Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer

Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment

“…Our drug release properties are consistent with the fact that in combination chemotherapy, PTX is administered before long-term administration of 5-FU. 3,4,6,8 In addition, less than 20% of 5-FU and PTX were released from our (5-FU+PTX)@FHPL at 37 °C and pH 6.8, in contrast to the release of 80% of DOX and 100% of PTX within 12 h from L-HMSNs under the same conditions. 41 These results conrm that drug release from (5-FU+PTX)@FHPL is pH-and temperature-responsive.…”

“…Recent studies have shown that paclitaxel (PTX) and 5-uorouracil (5-FU) can be synergistically used to treat breast and gastric cancer. [3][4][5][6][7][8] PTX is a hydrophobic drug commonly used for the treatment of breast, ovarian, and lung cancers. 9 However, its extremely poor water solubility requires the use of special solubilizers, such as Cremophor EL and absolute ethanol (1 : 1), 10 which lead to allergic reactions, signicantly limiting the application of PTX in cancer treatment.…”

“…12,13 In addition, they have different physicochemical properties and they require a xed sequence of administration during combination therapy: PTX must be administered before long-term administration of 5-FU. 3,4,6,8 These two factors make their co-delivery and controlled release challenging in the clinic.…”

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment

“…PTX and 5-FU are attractive options because of their distinct mechanisms of action, nonoverlapping toxicity, and potential synergy. Many studies have illustrated that PTX combined with 5-FU shows efficacy and tolerability for the treatment of certain solid tumors, particularly primary/metastatic breast carcinoma, drug-refractory ovarian cancers, and advanced/recurrent/metastatic gastric cancer [ 7 , 8 , 9 , 10 , 11 ]. Patients in these studies were treated with different dosages or routes: PTX was administered weekly, biweekly, or triweekly, while 5-FU was administered by bolus injection or continuous infusion with or without other chemotherapeutics in chemotherapy or a neoadjuvant or adjuvant setting [ 12 , 13 , 14 , 15 ].…”

Selective Killing of Cancer Cells by Nonplanar Aromatic Hydrocarbon‐Induced DNA Damage

“…[2a,3] Actually, traditional anticancer medicines remain the primary choices for most patients. Depending on the different mechanisms, the traditional anticancer agents can be classified into several categories: anti‐DNA synthesis and metabolism drugs (e.g., cisplatin, 5‐FU), protein synthesis inhibitors (e.g., asparaginase), mitotic disruptors (e.g., paclitaxel), etc. Nevertheless, the clinical use of these traditional anticancer medicines is normally limited by their low selectivity, serious side effects, and multidrug resistance .…”